WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 11-22

  Griesmann, Heidi ^a   Ripka, Stefanie ^a   Pralle, Moritz ^a   Ellenrieder, Volker ^a   Baumgart, Sandra ^a   Buchholz, Malte ^a   Pilarsky, Christian ^b   Aust, Daniela ^c   Gress, Thomas M ^a   Michl, Patrick ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; DOXYCYCLINE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OPEN READING FRAME; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 84873042539     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121312     Document Type: Article

References (49)

1. Logan CY and Nusse R (2004). The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20, 781-810.
2. Tanaka K, Kitagawa Y, and Kadowaki T (2002). Drosophila segment polarity gene product porcupine stimulates the posttranslational N-glycosylation of wingless in the endoplasmic reticulum. J Biol Chem 277(15), 12816-12823.
3. McDonald SL and Silver A (2009). The opposing roles of Wnt-5a in cancer. Br J Cancer 101(2), 209-214.
4. de Sousa EM, Vermeulen L, Richel D, and Medema JP (2011). Targeting wnt signaling in colon cancer stem cells. Clin Cancer Res 17(4), 647-653.
5. Wong GT, Gavin BJ, and McMahon AP (1994). Differential transformation of mammary epithelial cells by Wnt genes. Mol Cell Biol 14(9), 6278-6286.
6. Olson DJ and Gibo DM (1989). Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp Cell Res 241(1), 134-141.
7. Olson DJ, Oshimura M, Otte AP, and Kumar R (1998). Ectopic expression of wnt-5a in human renal cell carcinoma cells suppresses in vitro growth and telomerase activity. Tumour Biol 19(4), 244-252.
8. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R, and Jones SN (2003). Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4(5), 349-360.
9. Dejmek J, Safholm A, Kamp NC, Andersson T, and Leandersson K (2006). Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1α signaling in human mammary epithelial cells. Mol Cell Biol 26(16), 6024-6036.
10. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, and Trent JM (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3), 279-288.
11. Iozzo RV, Eichstetter I, and Danielson KG (1995). Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55(16), 3495-3499.
12. Lejeune S, Huguet EL, Hamby A, Poulsom R, and Harris AL (1995). Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1(2), 215-222.
13. Saitoh T, Mine T, and Katoh M (2002). Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9(5), 515-519.
14. Nishita M, Enomoto M, Yamagata K, and Minami Y (2010). Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol 20(6), 346-354.
15. Gordon MD and Nusse R (2006). Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281(32), 22429-22433.
16. Ripka S, Konig A, Buchholz M, Wagner M, Sipos B, Kloppel G, Downward J, Gress T, and Michl P (2007). WNT5A-target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28(6), 1178-1187.
17. Mikels AJ and Nusse R (2006). Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol 4(4), e115.
18. Li J, Ying J, Fan Y, Wu L, Ying Y, Chan AT, Srivastava G, and Tao Q (2010). WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 10(6), 617-624.
19. Murphy LL and Hughes CC (2002). Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the wnt/glycogen synthase kinase-3β pathway. J Immunol 169(7), 3717-3725.
20. Fromigue O, Hay E, Barbara A, and Marie PJ (2010). Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem 285(33), 25251-25258.
21. Mancini M and Toker A (2009). NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9(11), 810-820.
22. Fernandez-Zapico ME and Ellenrieder V (2010). NFAT transcription factors, the potion mediating "Dr. Jekill-Mr. Hyde" transformation of the TGFβ pathway in cancer cells. Cell Cycle 9(19), 3838-3839.
23. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, D'Arrigo C, Ryder K, Menke A, Gress T, et al. (2005). CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7(6), 521-532.
24. Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, et al. (2010). CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 59(8), 1101-1110.
25. Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S, and Real FX (1995). New pancreas cancers cell lines that represent distinct stages of ductal differentiation. Lab Invest 72(4), 395-404.
26. Strathdee CA, McLeod MR, and Hall JR (1999). Efficient control of tetracyclineresponsive gene expression from an autoregulated bi-directional expression vector. Gene 229(1-2), 21-29.
27. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, and Riccardi C (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139(2), 271-279.
28. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, Gress TM, and Ellenrieder V (2006). Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25(15), 3714-3724.
29. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL, and Moon RT (1996). Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 133(5), 1123-1137.
30. Martin V, Valencia A, Agirre X, Cervera J, San Jose-Eneriz E, Vilas-Zornoza A, Rodriguez-Otero P, Sanz MA, Herrera C, Torres A, et al. (2010). Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci 101(2), 425-432.
31. Dejmek J, Dejmek A, Safholm A, Sjolander A, and Andersson T (2005). Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65(20), 9142-9146.
32. Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, and Brabant G (2005). Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24(13), 2144-2154.
33. Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A, and Saldanha GS (2008). WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 14(18), 5825-5832.
34. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, and Kikuchi A (2006). Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66(21), 10439-10448.
35. Peng C, Zhang X, Yu H, Wu D, and Zheng J (2011). Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer 21(2), 280-288.
36. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, Oriss T, Gibson KF, Feghali-Bostwick C, and Kaminski N (2009). WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol 41(5), 583-589.
37. Jia L, Miao C, Cao Y, and Duan EK (2008). Effects of Wnt proteins on cell proliferation and apoptosis in HEK293 cells. Cell Biol Int 32(7), 807-813.
38. Almeida M, Han L, Bellido T, Manolagas SC, and Kousteni S (2005). Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280(50), 41342-41351.
39. Liang H, Coles AH, Zhu Z, Zayas J, Jurecic R, Kang J, and Jones SN (2007). Noncanonical Wnt signaling promotes apoptosis in thymocyte development. J Exp Med 204(13), 3077-3084.
40. Koenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, Singh G, Hofmann L, Kunsch S, Buch T, et al. (2010). NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 138(3), 1189-1199.
41. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, and Toker A (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4(7), 540-544.
42. Robbs BK, Cruz AL, Werneck MB, Mognol GP, and Viola JP (2008). Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 28(23), 7168-7181.
43. Saneyoshi T, Kume S, Amasaki Y, and Mikoshiba K (2002). The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature 417(6886), 295-299.
44. Bradley EW and Drissi MH (2010). WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-κB pathways. Mol Endocrinol 24(8), 1581-1593.
45. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, et al. (2010). Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18(1), 74-87.
46. Pedrosa AM, Weinlich R, Mognol GP, Robbs BK, Viola JP, Campa A, and Amarante-Mendes GP (2010). Melatonin protects CD4+ T cells from activationinduced cell death by blocking NFAT-mediated CD95 ligand upregulation. J Immunol 184(7), 3487-3494.
47. Alvarez S, Blanco A, Fresno M, and Munoz-Fernandez MA (2011). TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT. PLoS One 6(1), e16100.
48. Vashishta A, Habas A, Pruunsild P, Zheng JJ, Timmusk T, and Hetman M (2009). Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons. J Neurosci 29(48), 15331-15340.
49. Lin H, Sue YM, Chou Y, Cheng CF, Chang CC, Li HF, Cehn CC, and Juan SH (2010). Activation of a nuclear factor of activated T-lymphocyte-3 (NFAT3) by oxidative stress in carboplatin-mediated renal apoptosis. Br J Pharmacol 161(7), 1661-1676.